Avinger Inc (NASDAQ:AVGR) has received an average rating of “Buy” from the seven research firms that are presently covering the stock, Analyst Ratings Network.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $20.00.

AVGR has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Avinger from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a report on Thursday, October 15th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Avinger in a report on Thursday, October 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $18.00 price objective on shares of Avinger in a report on Thursday, October 15th. BTIG Research reaffirmed a “buy” rating on shares of Avinger in a report on Thursday, October 15th. Finally, Dougherty & Co downgraded shares of Avinger from a “buy” rating to a “neutral” rating in a report on Tuesday, December 29th.

Shares of Avinger (NASDAQ:AVGR) traded down 3.17% during trading on Monday, reaching $14.04. 9,494 shares of the company traded hands. The firm has a 50 day moving average of $18.65 and a 200 day moving average of $16.27. Avinger has a 52 week low of $9.35 and a 52 week high of $25.11. The stock’s market capitalization is $177.21 million.

Avinger (NASDAQ:AVGR) last released its quarterly earnings results on Thursday, November 5th. The medical device company reported ($1.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by $0.20. The company had revenue of $2.70 million for the quarter, compared to the consensus estimate of $3.10 million. On average, equities analysts predict that Avinger will post ($4.10) EPS for the current year.

In other Avinger news, Director Donald A. Lucas sold 4,000 shares of Avinger stock in a transaction dated Friday, December 11th. The shares were sold at an average price of $15.92, for a total transaction of $63,680.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John B. Ph D. Md Simpson sold 100,000 shares of Avinger stock in a transaction dated Wednesday, November 25th. The shares were sold at an average price of $17.26, for a total transaction of $1,726,000.00. The disclosure for this sale can be found here.

Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (NASDAQ:AVGR). The Company focuses to introduce products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and select European markets. The Company’s products include Lightbox imaging console, as well as Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The Company’s lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment.

12 Month Chart for NASDAQ:AVGR

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Avinger Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger Inc and related companies with MarketBeat.com's FREE daily email newsletter.